Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 15, 2025, Biogen (BIIB) has a market cap of $17.12 billion USD. According to our data, Biogen is ranked No.1054 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 15, 2025 | $17.12 B |
-23.16%
|
| Dec 31, 2024 | $22.28 B |
-40.91%
|
| Dec 29, 2023 | $37.71 B |
-6.55%
|
| Dec 30, 2022 | $40.35 B |
15.42%
|
| Dec 31, 2021 | $34.96 B |
-2.02%
|
| Dec 31, 2020 | $35.68 B |
-17.48%
|
| Dec 31, 2019 | $43.24 B |
-1.39%
|
| Dec 31, 2018 | $43.85 B |
-5.54%
|
| Dec 29, 2017 | $46.42 B |
12.34%
|
| Dec 30, 2016 | $41.32 B |
-7.43%
|
| Dec 31, 2015 | $44.64 B |
-9.75%
|
| Dec 31, 2014 | $49.46 B |
21.42%
|
| Dec 31, 2013 | $40.74 B |
91.00%
|
| Dec 31, 2012 | $21.33 B |
33.00%
|
| Dec 30, 2011 | $16.04 B |
64.13%
|
| Dec 31, 2010 | $9.77 B |
25.33%
|
| Dec 31, 2009 | $7.80 B |
12.32%
|
| Dec 31, 2008 | $6.94 B |
-16.32%
|
| Dec 31, 2007 | $8.29 B |
15.71%
|
| Dec 29, 2006 | $7.17 B |
8.64%
|
| Dec 30, 2005 | $6.60 B |
-32.02%
|
| Dec 31, 2004 | $9.71 B |
81.50%
|
| Dec 31, 2003 | $5.35 B |
10.64%
|
| Dec 31, 2002 | $4.83 B |
-51.88%
|
| Dec 31, 2001 | $10.04 B |
9.09%
|
| Dec 29, 2000 | $9.21 B |
92.94%
|
| Dec 31, 1999 | $4.77 B |
318.09%
|
| Dec 31, 1998 | $1.14 B |
36.73%
|
| Dec 31, 1997 | $0.83 B |
44.74%
|
| Dec 31, 1996 | $0.58 B |
21.79%
|
| Dec 29, 1995 | $0.47 B |
817.65%
|
| Dec 30, 1994 | $51.61 M |
-63.04%
|
| Dec 31, 1993 | $0.14 B |
-34.29%
|
| Dec 31, 1992 | $0.21 B |
-32.69%
|
| Dec 31, 1991 | $0.32 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Novartis
NVS
|
$217.12 B |
0.003 M
|
Switzerland
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
USA
|
 Merck
MRK
|
$197.26 B |
0.003 M
|
USA
|
 Pfizer
PFE
|
$127.27 B |
-0.003 M
|
USA
|
 Sanofi
SNY
|
$123.58 B |
-0.002 M
|
France
|
 Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
USA
|
 Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
USA
|
 AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
UK
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$128.67 B |
-0.003 M
|
USA
|
 AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
USA
|
 Teva Pharmaceutical Industries
TEVA
|
$15.60 B |
0.000 M
|
Israel
|
| Market Cap | = | BIIB Stock Price | * | BIIB Shares Outstanding |
| = | $116.98 | * | 0.15 B | |
| = | $17.12 B |